Roche's Actemra (tocilizumab) Receives Approval to Combat Coronavirus Complications in China
Shots:
- China’s National Health Commission reports in its treatment guidelines that Roche’s Actemra can be used to treat coronavirus patients with serious lung damage and high IL-6 levels
- Researchers are assessing Actemra in clinical studies & is expected to include 188 coronavirus patients and running until May 10- 2020- with the goal to evaluate efficacy and safety of the drug in coronavirus patients with CRS
- Actemra is a biologic therapy and has received the US FDA’s approval in 2010 for RA- act by inhibiting high IL-6 protein levels
Click here to read full press release/ article
Ref: Nasdaq | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com